DXSE:F:F-Xtrackers Stoxx Europe 600 Health Care Swap UCITS ETF 1C (EUR)

ETF | Others |

Last Closing

USD 226.1

Change

0.00 (0.00)%

Market Cap

USD 0.14B

Volume

1.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.15 (-0.57%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.26 (-0.51%)

USD 113.22B
SXR8:F iShares Core S&P 500 UCITS ETF..

+1.00 (+0.19%)

USD 83.51B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.30 (-0.56%)

USD 77.76B
FRCJ:F UBS MSCI Japan Socially Respon..

-0.14 (-0.63%)

USD 73.13B
EUNL:F iShares Core MSCI World UCITS ..

+0.09 (+0.09%)

USD 72.04B
SXRZ:F iShares VII PLC - iShares Nikk..

+0.10 (+0.04%)

USD 56.29B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.08 (-0.51%)

USD 54.81B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.04 (+0.05%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.22 (+0.24%)

USD 51.63B

ETFs Containing DXSE:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.59% 84% B 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.59% 82% B 67% D+
Trailing 12 Months  
Capital Gain 10.19% 58% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.19% 56% F 56% F
Trailing 5 Years  
Capital Gain 65.74% 86% B+ 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 65.74% 86% B+ 65% D
Average Annual (5 Year Horizon)  
Capital Gain 8.78% 79% B- 74% C
Dividend Return 8.78% 78% C+ 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.45% 65% D 85% B
Risk Adjusted Return 103.86% 99% N/A 97% N/A
Market Capitalization 0.14B 35% F 35% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.